Editorial: Innovative Therapeutic Strategies for Managing Diabetic Foot Ulcers and Mitigating Associated Complications
Summary: Published March 19, 2026 in Frontiers in Pharmacology (Vol. 17, IF 4.8), this editorial by Calvin A. Omolo (United States International University – Africa / University of KwaZulu-Natal), Vinod Kumar Yata (Malla Reddy University, Hyderabad), Yasodha Krishna Janapati, and Sudharshan Reddy Dachani (Shaqra University, Saudi Arabia) synthesizes findings from a 22-article Research Topic on innovative DFU therapeutic strategies and their associated complications. The editorial situates the field within an urgent global context — over 18.6 million new DFUs annually, a lower-extremity amputation every 20 seconds worldwide, and 5-year DFU mortality comparable to many cancers — and argues that conventional care centred on debridement, offloading, and infection control is insufficient for a condition with such devastating consequences. The editorial organises the 22 articles into five thematic pillars. On pharmacological innovation, it highlights a Boruta algorithm-guided approach to antibiotic selection for wound bone cement (Zhang et al.) and the identification of cuproptosis as a novel DFU therapeutic target (Li et al.). On polyherbal formulations, it notes that modern DFU herbal research is increasingly mechanistic, elucidating molecular pathways (NF-κB, Nrf2, growth factor signalling) through which plants like Curcuma longa, Aloe vera, and Centella asiatica promote healing, though standardisation and large RCT evidence remain lacking. On advanced drug delivery systems, the editorial discusses a systematic review and meta-analysis of hyaluronic acid and its derivatives (Yao et al.) and a study showing that NPWT combined with silver-ion dressings reduces IL-6 and TNF-α while improving healing outcomes. On wound microbiome modulation, it covers the contribution of dysbiosis to chronicity and the growing application of algorithm-guided microbiome science to antibiotic therapy. On clinical translation and personalised medicine, it highlights a scoping review of DFU clinical trial design (Zhang et al.) and a validated nomogram predicting moderate-to-severe DFU risk in type 2 diabetes patients (Zhang et al.). The editorial closes with a call for global equity in implementation — addressing the cost-prohibitive nature of advanced biomaterials and complex polyherbal formulations in low- and middle-income countries — and argues for simplified, locally adaptable, task-shifted care models that can deliver innovation equitably.
Key Highlights:
- Global DFU burden framing: 18.6 million new ulcers annually, one amputation every 20 seconds worldwide, 5-year mortality rivalling multiple common cancers — yet DFU recurrence and its consequences remain normalised in clinical culture, which the editorial explicitly critiques
- Precision pharmacology: algorithm-guided microbiome analysis for antibiotic selection in wound bone cement (moving away from empirical treatment) and cuproptosis as a novel mechanistic DFU target — both requiring substantial further validation before clinical readiness
- Polyherbal and natural formulations: key wound-healing herbs (*Curcuma longa*, *Aloe vera*, *Centella asiatica*) showing mechanistic molecular evidence (NF-κB, Nrf2, growth factor signalling), but lacking standardised extracts and large-scale RCTs with hard endpoints such as amputation prevention
- Advanced biomaterials: hyaluronic acid derivatives (systematic review confirming moist wound environment maintenance and controlled drug/growth factor release); NPWT + silver-ion dressings (reduced IL-6, TNF-α, and improved healing) — both showing promise but facing cost and regulatory complexity barriers
- Clinical translation tools: a scoping review of DFU clinical trial design flaws; a nomogram for individual moderate-to-severe DFU risk prediction in type 2 diabetes patients — both addressing the gap between laboratory innovation and bedside implementation
- Global equity imperative: the editorial explicitly calls for parallel development of simplified, affordable, locally sourced adaptations of advanced therapies, including low-cost point-of-care diagnostics, standardised herbal products, and task-shifted care models, to prevent innovation from widening existing health disparities
Keywords: diabetic foot ulcer pharmacology, DFU wound microbiome, polyherbal DFU treatment, hyaluronic acid wound healing, precision medicine diabetic foot, DFU global amputation burden
Calvin A. Omolo, Vinod Kumar Yata, Yasodha Krishna Janapati, Sudharshan Reddy Dachani